PMID- 26381272
OWN - NLM
STAT- MEDLINE
DCOM- 20161108
LR  - 20181202
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 32
IP  - 2
DP  - 2016 Feb
TI  - Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease 
      in patients with type 2 diabetes mellitus: a systematic review and meta-analysis 
      of randomized and non-randomized studies.
PG  - 200-16
LID - 10.1002/dmrr.2713 [doi]
AB  - BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has a high prevalence in 
      patients with type 2 diabetes mellitus (T2DM). In this study, we sought to 
      provide a comprehensive assessment regarding the effects of anti-diabetic agents 
      on NAFLD in patients with T2DM. METHODS: MEDLINE, EMBASE and the Cochrane Central 
      Register of Controlled Trials were searched for randomized controlled trials 
      (RCTs) with different anti-diabetic agents in T2DM. Observational trials were 
      also recruited to expand our population. Hepatic fat content and liver histology 
      were evaluated as primary outcomes. Pooled estimates were calculated using a 
      fixed effect model. RESULTS: One thousand one hundred ninety-six participants in 
      19 RCTs and 14 non-randomized studies were included. Evidence from RCTs and 
      observational studies suggested that greater hepatic fat content reduction and 
      improved liver histology were seen in thiazolidinediones for 12-72 weeks; 
      glucagon-like peptide-1 receptor agonists had beneficial effects on hepatic fat 
      content after 26-50 weeks intervention, and insulin/metformin combination with 
      3-7 months improved hepatic fat content. Initiating metformin or dapagliflozin 
      showed no benefit on hepatic fat content or liver histology in 16-48 weeks. 
      Besides, nateglinide for 18 months was reported in a small sample-size RCT to 
      improve hepatic fat content and liver histology. Sitagliptin therapy of 1 year 
      also provided benefit on nonalcoholic steatohepatitis score in an observational 
      study. CONCLUSIONS: For T2DM with NAFLD, administrating thiazolidinediones and 
      glucagon-like peptide-1 receptor agonists seems to provide more identified 
      advances in attenuating hepatic fat content. Further RCTs are warranted to assess 
      the efficacy of various hypoglycemic agents on clinical outcomes associated with 
      NAFLD in T2DM. Copyright (c) 2015 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2015 John Wiley & Sons, Ltd.
FAU - Tang, Wenjuan
AU  - Tang W
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Xu, Qianyue
AU  - Xu Q
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Hong, Ting
AU  - Hong T
AD  - Department of Endocrinology, Drum Tower Clinical Medical College of Nanjing 
      Medical University, Nanjing, China.
FAU - Tong, Guoyu
AU  - Tong G
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Feng, Wenhuan
AU  - Feng W
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Shen, Shanmei
AU  - Shen S
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Bi, Yan
AU  - Bi Y
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
FAU - Zhu, Dalong
AU  - Zhu D
AD  - Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University 
      Medical School, Nanjing, China.
AD  - Department of Endocrinology, Drum Tower Clinical Medical College of Nanjing 
      Medical University, Nanjing, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20151101
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy
MH  - Prognosis
OTO - NOTNLM
OT  - anti-diabetic agents
OT  - meta-analysis
OT  - nonalcoholic fatty liver disease
OT  - type 2 diabetes mellitus
EDAT- 2015/09/19 06:00
MHDA- 2016/11/09 06:00
CRDT- 2015/09/19 06:00
PHST- 2015/04/04 00:00 [received]
PHST- 2015/07/10 00:00 [revised]
PHST- 2015/07/23 00:00 [accepted]
PHST- 2015/09/19 06:00 [entrez]
PHST- 2015/09/19 06:00 [pubmed]
PHST- 2016/11/09 06:00 [medline]
AID - 10.1002/dmrr.2713 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2016 Feb;32(2):200-16. doi: 10.1002/dmrr.2713. Epub 2015 
      Nov 1.